Coming soon! Phase 2 trial of an oral treatment for dry AMD
Cognition Therapeutics, Inc. is developing a pipeline of drug candidates that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. The company’s candidates work by binding to protein components of the sigma-2 (σ-2) receptor complex, which is present on synapses in the CNS and retina and acts as a key regulator of cellular damage and stress response. Receptor component proteins (PGRMC1 and TMEM97) control autophagy, cholesterol synthesis and lipid membrane-bound protein trafficking, all of which are associated with age-related disorders of the CNS and retina.